|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Targeting HER2-positive breast cancer with trastuzumab-DM1 ,an antibody- cytotoxic drug conjugate 显示文摘 | LEWIS PHILLIPS GD LI G DUGGER DL | 2008 | Cancer Res2008，68，22： | 1 |
| 2 | Targeting HER2-posi- tive breast cancer with Trastuzumab-DM1, an antibody-cytotoxic drug conjugate 显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 3 | Targeting HER2-positive breast cancer with trastuzumab-DM1,an antibody-cytotoxic drug conjugate显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 4 | Relationship between tumor biomark- ers and efficacy in EMILIA, a phase iii study of trastuzumab emtansine in HER2-Positive metastatic breast cancer 显示文摘 | Baselga J Lewis Phillips GD | 2016 | Clin Cancer Res2016，26，： | 1 |
| 5 | Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibody- cytotoxic drug conjugate显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 6 | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate显示文摘 | Lewis Phillips GD Li G Dugger DL | | 0，，22： | 1 |
| 7 | Targetjng HER2 positive breast cancer with trastuzumab-DM1,an antibodv-cyto-toxic drug conjugate显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 8 | The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates显示文摘 | Erickson HK Lewis Phillips GD Leipold DD | 2012 | Mol Cancer Ther2012，11，5： | 1 |
| 9 | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cyto- toxic drug conjugate 显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 10 | Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibody- cytotoxic drug conjugate 显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，： | 1 |
| 11 | Targeting HER2-positive breast cancer with trastuzumab-DM1,an antibody-cytotoxic drug conjugate显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，： | 1 |
| 12 | Targeting HER2-positive breast cancer with trastuzumab-DMl,an antibody-cytotoxic drug conjugate 显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 13 | Targeting HER2- positive breast cancer with trastuzumab DM1, an antibody- cytotoxic drug conjugate 显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，： | 1 |
| 14 | Targeting Her2- positive breast cancer with trastuzumab-DMl , an antibodycytotoxic drug conjugate 显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 15 | Relationship Between Tumor Biomarkers and Efficacy in EMILIA, a Phase IlI'Study of Tmstuzumab Emtansine in HER2-Positive Metastatic Breast Cancer 显示文摘 | Baselga J Lewis Phillips GD Verrna S | 2016 | Clin Cancer Res2016，，： | 1 |
| 16 | Targeting HER2-positive breast cancer with trastuzumab-DM1,anantibody-cytotoxicdrug conjugate显示文摘 | Lewis Phillips GD Li g Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 17 | Targeting HER-2-posi- rive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate显示文摘 | Lewis phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 18 | Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate 显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 19 | Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibody- cytotoxic drug conjugate 显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
| 20 | Targeting HER2--posi- tire breast cancer with trastuzumab-DM1, an antibody--cytotoxic drug conjugate显示文摘 | Lewis Phillips GD Li G Dugger DL | 2008 | Cancer Res2008，68，22： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员